Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776604 | 0.95 | PTPN11 (0.54) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL4940300 | 0.88 | KDM4E (0.55) | CA12CA2CA7CA9CA14 | |
| SCHEMBL709231 | 0.86 | LCK (0.62) | CA12CA2CA7CA9CA14 | |
| SCHEMBL3145033 | 0.85 | LCK (0.49) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL17585028 | 0.83 | NPC1 (0.49) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL12015399 | 0.83 | PTPN11 (0.55) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL9939192 | 0.83 | EGFR (0.51) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL19829368 | 0.80 | PTPN11 (0.47) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL30917343 | 0.80 | PTPN11 (0.53) | CYP4A11CA12CA2CA7CA9 | |
| SCHEMBL7440151 | 0.80 | PTPN11 (0.53) | CYP4A11CA12CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2010-04-01 | — | — | US | disclosed |
| CN-101595091-A | 1-naphthyl alkylpiperidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-12-02 | — | — | CN | disclosed |
| EP-2098509-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| CN-1278793-A | Sulfonyl derivatives | DAIICHI SEIYAKU CO (JP) | 2001-01-03 | — | — | CN | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | CYP4A11 1281/4885CA12 3106/4885CA2 2790/4885 |
| US-20100081825-A1 | 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE | MCHR1, MCHR2, MC5R | CYP4A11 784/4885CA12 4176/4885CA2 3530/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | CYP4A11 1574/4885CA12 4368/4885CA2 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.